Skip to main content
Smart Investors Daily
Bone Biologics Corporation logo

NASDAQ · BBLG

Bone Biologics Corporation

Healthcare · Medical - Devices

$0.39

Down-$0.01 (-2.66%)

Updated Oct 24, 2026, 11:40 PM

SID Score

2.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
3.38M
P/E ratio
-0.86
Dividend yield
0.00%
52-week range
$0.38 – $2.39
Volume
9.97K
Avg. volume
80.04K

Price performance · BBLG

BBLG price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 23, 2026

BBLG closed at $0.39 after 21 trading sessions, down 20.40% for the selected period.

Last close
$0.39
Period change
-20.40%
Period low
$0.39
Period high
$0.50
Daily close
View OHLC price history
BBLG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 23, 2026$0.4068$0.4068$0.391$0.39489.97K
Oct 22, 2026$0.41$0.4167$0.3917$0.405625.14K
Oct 21, 2026$0.405$0.4245$0.405$0.4215.65K
Oct 20, 2026$0.425$0.4427$0.411$0.4314.53K
Oct 19, 2026$0.43$0.4427$0.3901$0.410519.15K
Oct 16, 2026$0.405$0.409$0.385$0.39559.75K
Oct 15, 2026$0.3966$0.404$0.3788$0.3876119.54K
Oct 14, 2026$0.4182$0.4182$0.391$0.414658.19K
Oct 13, 2026$0.442$0.46$0.4003$0.4359.62K
Oct 12, 2026$0.4661$0.4661$0.4401$0.455133.85K
Oct 9, 2026$0.4705$0.4922$0.4583$0.467136.82K
Oct 8, 2026$0.475$0.4751$0.468$0.46919.69K
Oct 7, 2026$0.462$0.4875$0.462$0.487518.6K
Oct 6, 2026$0.496$0.4962$0.462$0.479553.8K
Oct 5, 2026$0.4744$0.4954$0.46$0.485226.26K
Oct 2, 2026$0.4788$0.4811$0.466$0.475420.91K
Oct 1, 2026$0.47$0.4812$0.4663$0.47523.5K
Sep 30, 2026$0.491$0.4963$0.4751$0.496336.7K
Sep 29, 2026$0.486$0.4963$0.4792$0.496315.97K
Sep 28, 2026$0.4795$0.4963$0.4795$0.496333.44K
Sep 25, 2026$0.4879$0.4963$0.47$0.49659.77K

Latest BBLG news

The latest Smart Investors Daily articles mentioning BBLG.

BBLG research

Overview

Company profile and research snapshot.

Company profile

Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has applications in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BBLG recent ratings
DateFirmRatingTarget
Apr 13, 2023EF HuttonBuy—
Apr 3, 2023EF HuttonBuy—
Oct 18, 2022EF HuttonBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Jan 8, 2026

Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook

Key accomplishments include expanded rhNELL-1 shelf life, advanced NB1 development, strengthened balance sheet, and maintained Nasdaq complianceBURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today summarized key corporate, scientific, and operational milestones achieved during 2025 and outlined its strategic outlook for 2026. “We executed wit

defenseworld.net · Dec 11, 2025

Bone Biologics (NASDAQ:BBLG) Shares Down 0.5% – Should You Sell?

Bone Biologics Corp. (NASDAQ: BBLG - Get Free Report)'s share price fell 0.5% during trading on Wednesday. The stock traded as low as $1.9246 and last traded at $2.10. 43,801 shares were traded during trading, an increase of 8% from the average session volume of 40,407 shares. The stock had previously closed at $2.11. Analyst

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.